North America Glycomic Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis ByClass (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT),Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]

No. of Pages: 193    |    Report Code: BMIRE00027508    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Glycomic Therapeutics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Glycomic Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Glycomic Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Increasing research in glycomics
  • 5.1.2 Rising demand for personalized medicine
  • 5.1.3 Technological advancements in glycan analysis
5.2 Market Opportunities
  • 5.2.1 Expanding application in cancer treatments
  • 5.2.2 Growth in precision medicine market
  • 5.2.3 Development of glycan-based therapeutics
5.3 Future Trends
  • 5.3.1 Focus on glycan biomarker discovery
  • 5.3.2 Advancements in glycosylation research
  • 5.3.3 Integration with gene therapies
5.4 Impact of Drivers and Restraints

6. North America Glycomic Therapeutics Market Regional Analysis

6.1 North America Glycomic Therapeutics Market Overview
6.2 North America Glycomic Therapeutics Market Revenue 2020-2028 (US$ Million)
6.3 North America Glycomic Therapeutics Market Forecast Analysis

7. North America Glycomic Therapeutics Market Analysis – by Class

7.1 Isolated and Synthetic
  • 7.1.1 Overview
  • 7.1.2 Isolated and Synthetic: North America Glycomic Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Glycomic Therapeutics Market Analysis – by Structures

8.1 Glycoproteins
  • 8.1.1 Overview
  • 8.1.2 Glycoproteins: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Targeting Sialic Acid
  • 8.2.1 Overview
  • 8.2.2 Targeting Sialic Acid: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Proteoglycans
  • 8.3.1 Overview
  • 8.3.2 Proteoglycans: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Targeting Glycosaminoglycans
  • 8.4.1 Overview
  • 8.4.2 Targeting Glycosaminoglycans: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Glycosylphosphatidylinositol-Anchored Proteins & Heparin Based Glycans
  • 8.5.1 Overview
  • 8.5.2 Glycosylphosphatidylinositol-Anchored Proteins & Heparin Based Glycans: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Targeting Glycosphingolipids
  • 8.6.1 Overview
  • 8.6.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Glycomic Therapeutics Market Analysis – by Indications

9.1 Thrombosis & Chemoprophylaxis
  • 9.1.1 Overview
  • 9.1.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Anaemia
  • 9.2.1 Overview
  • 9.2.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Anti-Adhesive & Anti-Inflammatory
  • 9.3.1 Overview
  • 9.3.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Cataracts
  • 9.4.1 Overview
  • 9.4.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Gaucher's Disease
  • 9.5.1 Overview
  • 9.5.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.6 MPS-1 & IV
  • 9.6.1 Overview
  • 9.6.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Cancer
  • 9.7.1 Overview
  • 9.7.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.8 Alzheimer's Disease
  • 9.8.1 Overview
  • 9.8.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.9 Influenza Type A & B
  • 9.9.1 Overview
  • 9.9.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Glycomic Therapeutics Market – North America Analysis

10.1 North America
  • 10.1.1 North America Glycomic Therapeutics Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 10.1.1.1 North America Glycomic Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 US: North America Glycomic Therapeutics Market Breakdown, by Class
    • 10.1.1.1.2 US: North America Glycomic Therapeutics Market Breakdown, by Structures
    • 10.1.1.1.3 US: North America Glycomic Therapeutics Market Breakdown, by Indications
  • 10.1.1.2 Canada: North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Canada: North America Glycomic Therapeutics Market Breakdown, by Class
    • 10.1.1.2.2 Canada: North America Glycomic Therapeutics Market Breakdown, by Structures
    • 10.1.1.2.3 Canada: North America Glycomic Therapeutics Market Breakdown, by Indications
  • 10.1.1.3 Mexico : North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Glycomic Therapeutics Market Breakdown, by Class
    • 10.1.1.3.2 Mexico : North America Glycomic Therapeutics Market Breakdown, by Structures
    • 10.1.1.3.3 Mexico : North America Glycomic Therapeutics Market Breakdown, by Indications

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Glycomic Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 BioMarin Pharmaceutical Inc.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Genzyme Corporation (Sanofi)
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Halozyme Therapeutics, Inc.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Bayer AG
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Alzheon, Inc.
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 GlycoMar
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 GlaxoSmithKline plc.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 F.Hoffmann-La Roche Ltd
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - North America Glycomic Therapeutics Market

  1. BioMarin Pharmaceutical Inc.                    
  2. Genzyme Corporation (Sanofi)                 
  3. Halozyme Therapeutics, Inc.                      
  4. Bayer AG                                                            
  5. Alzheon, Inc.                                                     
  6. GlycoMar                                                           
  7. GlaxoSmithKline plc.                   
  8. F. Hoffmann-La Roche Ltd           
north-america-glycomic-therapeutics-market